Amado Rafael's Form 4 filing
Zai Lab Ltd (ZLAB) · filed Jan 2, 2025
- Accession no.
- 0000905148-25-000011
- Filed
- Jan 2, 2025
- Trade date
- Dec 30-31, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $199.3K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Amado RafaelCIK 0001662119 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | American Depositary Shares | MOption exerciseAcquired | +21,000 | –F3 | – | 41,417 | Direct | |
| Dec 31, 2024 | American Depositary Shares | SSaleDisposed | −7,583 | $26.28 | −$199,281.24 | 33,834 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | American Depositary Shares | MOption exerciseDisposed | −21,000 | $0.00 | $0 | 63,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Each RSU represents a contingent right to receive one ADS.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Head of Global Oncology Research and Development